Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Alessandro Testori, Célèste Lebbé et al.|The Lancet Oncology|2015

Cited by 1.3k